Optimizing chemotherapy by measuring reversal of P-glycoprotein activity in plasma membrane vesicles

Biotechnology and Bioengineering

Volumn 81, Issue 5, 2003, Pages 507-517

  Köhler, Sabine ^a,b   Stein, Wilfred D ^a,b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b MDR Tests Ltd   (Israel)

Author keywords

Membrane preparation; Multidrug resistance; P glycoprotein; P gp blockers

Indexed keywords

ASSAYS; CELLS; CHEMOTHERAPY; OPTIMIZATION; PATIENT TREATMENT; TUMORS;

MULTIDRUG RESISTANCE;

PROTEINS;

BLOCKING AGENT; CALCEIN; GLYCOPROTEIN P; RHODAMINE; TARIQUIDAR; UNCLASSIFIED DRUG; VERAPAMIL;

ANALYTIC METHOD; ARTICLE; CELL ASSAY; CELL LINE; CELL MEMBRANE; CHEMOTHERAPY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG BINDING; DRUG EFFICACY; DRUG TRANSPORT; HUMAN; HUMAN CELL; ISOLATION PROCEDURE; LYMPHOBLAST; MEMBRANE VESICLE; PLASMA; PROTEIN ANALYSIS;

ADENOSINE TRIPHOSPHATASES; ANTINEOPLASTIC AGENTS; BINDING, COMPETITIVE; BIOLOGICAL ASSAY; BIOLOGICAL TRANSPORT; CELL MEMBRANE; CELL SURVIVAL; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY; EQUIPMENT DESIGN; HUMANS; LEUKEMIA, T-CELL; MEMBRANE PROTEINS; P-GLYCOPROTEIN; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS; RHODAMINES; SENSITIVITY AND SPECIFICITY; TRANSPORT VESICLES; TUMOR CELLS, CULTURED;

EID: 0037420343     PISSN: 00063592     EISSN: None     Source Type: Journal    
DOI: 10.1002/bit.10488     Document Type: Article

References (39)

1. Ayesh S, Lyubimov E, Algour N, Stein WD. 1996a. Reversal of P-glycoprotein is greatly reduced by the presence of plasma but can be monitored by an ex vivo clinical assay. Anti-Cancer Drugs 7:678-686.
2. Ayesh S, Shao Y-M, Stein WD. 1996b. Co-operative, competitive and non-competitive interactions between modulators of P-glycoprotein. Biochim Biophys Acta 1316:8-18.
3. Bebawy M, Morris MB, Roufogalis BD. 1999. A continuous fluorescence assay for the study of P-glycoprotein-mediated drug efflux using inside-out membrane vesicles. Anal Biochem 268:270-277.
4. Borgnia MJ, Eytan GD, Assaraf YG. 1996. Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. J Biol Chem 271:3163-3171.
5. Bradford MM. 1967. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
6. Braybrooke JP, Vallis KA, Houlbrook S, Rockett H, Ellmen J, Anttila M, Ganesan TS, Harris AL, Talbot DC. 2000. Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine. Cancer Chemother Pharmacol 46:27-34.
7. Broxterman HJ, Kuiper CM, Schuurhuis GJ, van der Hoeven JJ, Pinedo HM, Lankelma J. 1987. Daunomycin accumulation in resistant tumor cells as a screening model for resistance modifying drugs: role of protein binding. Cancer Lett 35:87-95.
8. Chico I, Kang MH, Bergan R, Abraham J, Bakke S, Meadows B, Rutt A, Robey R, Choyke P, Merino M, Goldspiel B, Smith T, Steinberg S, Figg WD, Fojo T, Bates S. 2001. Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833. J Clin Oncol 19:832-842.
9. Cho CW, Liu Y, Yan X, Henthorn T, Ng KY. 2000. Carrier-mediated uptake of rhodamine 123: implications on its use for MDR research. Biochem Biophys Res Commun 279:124-130.
10. Doige CA, Ames GF. 1993. ATP-dependent transport systems in bacteria and humans: relevance to cystic fibrosis and multidrug resistance. Annu Rev Microbiol 47:291-319.
11. Dong M, Penin F, Baggetto LG. 1996. Efficient purification and reconstitution of P-glycoprotein for functional and structural studies. J Biol Chem 271:28875-28883.
12. Endicott JA, Ling V. 1989. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58:137-171.
13. Eneroth A, Astrom E, Hoogstraate J, Schrenk D, Conrad S, Kauffmann HM, Gjellan K. 2001. Evaluation of a vincristine resistant Caco-2 cell line for use in a calcein AM extrusion screening assay for P-glycoprotein interaction. Eur J Pharm Sci 12:205-214.
14. Essodaigui M, Broxterman HJ, Garnier-Suillerot A. 1998. Kinetic analysis of calcein and calcein-acetoxymethylester efflux mediated by the multidrug resistance protein and P-glycoprotein. Biochemistry 37: 2243-2250.
15. Essodaigui M, Frezard F, Moreira ES, Dagger F, Garnier-Suillerot A. 1999. Energy-dependent efflux from Leishmania promastigotes of substrates of the mammalian multidrug resistance pumps. Mol Biochem Parasitol 100:73-84.
16. Kerr KM, Sauna ZE, Ambudkar SV. 2001. Correlation between steady-state ATP hydrolysis and vanadate-induced ADP trapping in Human P-glycoprotein. Evidence for ADP release as the rate-limiting step in the catalytic cycle and its modulation by substrates. J Biol Chem 276:8657-8664.
17. Kessel M, Gieseler F, Woodcock BG. 1999. Influence of serum protein binding on the uptake and retention of idarubicin by sensitive and multidrug resistant human leukemic cells. Eur J Clin Pharmacol 55: 369-373.
18. Lan L-B, Ayesh S, Lyubimov E, Pashinsky I, Stein WD. 1996. Kinetic parameters for reversal of the multidrug pump as measured for drug accumulation and cell killing. Cancer Chemother Pharmacol 38: 181-190.
19. Lehnert M, de Giuli R, Kunke K, Emerson S, Dalton WS, Salmon SE. 1996. Serum can inhibit reversal of multidrug resistance by chemosensitisers. Eur J Cancer 32A:862-867.
20. Leyland-Jones B, Dalton W, Fisher GA, Sikic BI. 1993. Reversal of multidrug resistance to cancer chemotherapy. Cancer 72:3484-3488.
21. Lin JT, Sharma R, Grady JJ, Awasthi S. 2001. A flow cell assay for evaluation of whole cell drug efflux kinetics: analysis of paclitaxel efflux in CCRF-CEM leukemia cells overexpressing P-glycoprotein. Drug Metab Dispos 29:103-110.
22. List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon S, Futscher B, Baier M, Dalton W. 1993. Phase-I/II Trial of Cyclosporine as a Chemotherapy-Resistance Modifier in Acute Leukemia. J Clin Oncol 11:1652-1660.
23. Litman T, Druley TE, Stein WD, Bates S E. 2001. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 58:931-959.
24. Litman T, Zeuthen T, Skovsgaard T, Stein WD. 1997. Competitive, noncompetitive and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activity. Biochim Biophys Acta 1361:169-176.
25. Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE. 1991. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 9:17-24.
26. Mistry P, Stewart AJ, Dangerfield W, Okiji S, Liddle C, Bootle D, Plumb JA, Templeton D, Charlton P. 2001. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res 61:749-758.
27. Nociari MM, Shalev A, Benias P, Russo C. 1998. A novel one-step, highly sensitive fluorometric assay to evaluate cell-mediated cytotoxicity. J Immunol Methods 15:157-67.
28. Parasrampuria DA, Lantz MV, Benet LZ. 2001. A human lymphocyte based ex vivo assay to study the effect of drugs on P-glycoprotein (P-gp) function. Pharm Res 18:39-44.
29. Ruth A, Stein WD, Rose E, Roninson IB. 2001. Coordinate changes in drug resistance and drug-induced conformational transitions in altered-function mutants of the multidrug transporter P-glycoprotein. Biochemistry 40:4332-4339.
30. Safa AR. Stern RK, Choi K, Agresti M, Tamai I, Mehta ND, Roninson IB. 1990. Molecular basis of preferential resistance to colchicine in multidrug-resistant human cells conferred by Gly-185 - Val-185 substitution in P-glycoprotein. Proc Natl Acad Sci USA 87:7225-7229.
31. Sauna ZE, Ambudkar SV. 2001. Characterization of the catalytic cycle of ATP hydrolysis by human P-glycoprotein. The two ATP hydrolysis events in a single catalytic cycle are kinetically similar but affect different functional outcomes. J Biol Chem 276:11653-11661.
32. Sharom FJ, Lu P, Liu R, Yu X. 1998. Linear and cyclic peptides as substrates and modulators of P-glycoprotein: peptide binding and effects on drug transport and accumulation. Biochemical J 333:621-630.
33. Shepard RL, Winter MA, Hsaio SC, Pearce HL, Beck WT, Dantzig AH. 1998. Effect of modulators on the ATPase activity and vanadate nucleotide trapping of human P-glycoprotein. Biochem Pharmacol 56: 719-727.
34. Stein WD, Kott MV. 2001. Ex-vivo test kit for testing the effectiveness of reversers of multidrug resistance. Us patent US 6258526 B1.
35. Stewart A, Steiner J, Mellows G, Laguda B, Norris D, Bevan P. 2000a. Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration. Clin Cancer Res 6:4186-4191.
36. Stewart A, Steiner J, Mellows G, Laguda B, Norris D, Bevan P. 2000b. Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration. Clin Cancer Res 6:4186-4191.
37. Wishart GC, Plumb JA, Morrison JG, Hamilton TG, Kaye SB. 1992. Adequate tumour quinidine levels for multidrug resistance modulation can be achieved in vivo. Eur J Cancer 28:28-31.
38. Yang JM, Goldenberg S, Gottesman MM, Hait WN. 1994. Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists. Cancer Res 54:730-737.
39. Zehrer C, Beck J, Gekeler V, lhle J, Holzer U, Dohlsten M, Kalland T, Niethammer D, Dannecker GE. 1996. Superantigen-mediated cellular cytotoxicity is dependent on antigen expression, but independent of the P-glycoprotein multidrug resistance phenotype. Br J Haematol 95: 452-456.